{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:29:02Z","timestamp":1790724542653,"version":"4.1.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T00:00:00Z","timestamp":1729555200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T00:00:00Z","timestamp":1729555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2023R1A2C2006375"],"award-info":[{"award-number":["NRF-2023R1A2C2006375"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2023R1A2C2004339"],"award-info":[{"award-number":["NRF-2023R1A2C2004339"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000015","name":"Canadian Cancer Society Research Institute","doi-asserted-by":"publisher","award":["CHA-#707351"],"award-info":[{"award-number":["CHA-#707351"]}],"id":[{"id":"10.13039\/501100000015","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009326","name":"Cancer Research Society","doi-asserted-by":"publisher","award":["CRS-839202"],"award-info":[{"award-number":["CRS-839202"]}],"id":[{"id":"10.13039\/100009326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-024-53347-6","type":"journal-article","created":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T07:02:30Z","timestamp":1729580550000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Oral reovirus reshapes the gut microbiome and enhances antitumor immunity in colon cancer"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2753-5294","authenticated-orcid":false,"given":"Won Suk","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Joon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye Jin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2252-7041","authenticated-orcid":false,"given":"Hannah","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun-Jin","family":"Go","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enkhtaivan","family":"Gansukh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki-Hoon","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9894-9104","authenticated-orcid":false,"given":"Dong Guk","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommy","family":"Alain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6979-5812","authenticated-orcid":false,"given":"Hong Jae","family":"Chon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9780-6155","authenticated-orcid":false,"given":"Chan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,22]]},"reference":[{"key":"53347_CR1","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41571-022-00719-w","volume":"20","author":"SZ Shalhout","year":"2023","unstructured":"Shalhout, S. Z., Miller, D. M., Emerick, K. S. & Kaufman, H. L. Therapy with oncolytic viruses: progress and challenges. Nat. Rev. Clin. Oncol. 20, 160\u2013177 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"53347_CR2","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1016\/j.ymthe.2020.04.013","volume":"28","author":"JC Bell","year":"2020","unstructured":"Bell, J. C. Check and checkmate: battling cancer with multiplex immunotherapy. Mol. Ther. 28, 1236\u20131237 (2020).","journal-title":"Mol. Ther."},{"key":"53347_CR3","doi-asserted-by":"publisher","first-page":"421","DOI":"10.3390\/v10080421","volume":"10","author":"T Bourhill","year":"2018","unstructured":"Bourhill, T., Mori, Y., Rancourt, D. E., Shmulevitz, M. & Johnston, R. N. Going (Reo)viral: factors promoting successful reoviral oncolytic infection. Viruses 10, 421 (2018).","journal-title":"Viruses"},{"key":"53347_CR4","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1158\/0008-5472.CAN-15-3308","volume":"78","author":"M Kim","year":"2018","unstructured":"Kim, M. et al. Amplification of oncolytic vaccinia virus widespread tumor cell killing by sunitinib through multiple mechanisms. Cancer Res. 78, 922\u2013937 (2018).","journal-title":"Cancer Res."},{"key":"53347_CR5","doi-asserted-by":"publisher","first-page":"7743","DOI":"10.3390\/ijms21207743","volume":"21","author":"CM Oh","year":"2020","unstructured":"Oh, C. M., Chon, H. J. & Kim, C. Combination immunotherapy using oncolytic virus for the treatment of advanced solid tumors. Int. J. Mol. Sci. 21, 7743 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"53347_CR6","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/nrc.2016.14","volume":"16","author":"BS Parker","year":"2016","unstructured":"Parker, B. S., Rautela, J. & Hertzog, P. J. Antitumour actions of interferons: implications for cancer therapy. Nat. Rev. Cancer 16, 131\u2013144 (2016).","journal-title":"Nat. Rev. Cancer"},{"key":"53347_CR7","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/nm.3848","volume":"21","author":"CS Ilkow","year":"2015","unstructured":"Ilkow, C. S. et al. Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity. Nat. Med. 21, 530\u2013536 (2015).","journal-title":"Nat. Med."},{"key":"53347_CR8","doi-asserted-by":"publisher","DOI":"10.1172\/JCI143296","volume":"131","author":"M von Locquenghien","year":"2021","unstructured":"von Locquenghien, M., Rozalen, C. & Celia-Terrassa, T. Interferons in cancer immunoediting: sculpting metastasis and immunotherapy response. J. Clin. Investig. 131, e143296 (2021).","journal-title":"J. Clin. Investig."},{"key":"53347_CR9","doi-asserted-by":"publisher","first-page":"e000857","DOI":"10.1136\/jitc-2020-000857","volume":"8","author":"YS Lee","year":"2020","unstructured":"Lee, Y. S. et al. Oncolytic vaccinia virus reinvigorates peritoneal immunity and cooperates with immune checkpoint inhibitor to suppress peritoneal carcinomatosis in colon cancer. J. Immunother. Cancer 8, e000857 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"53347_CR10","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.trecan.2015.10.004","volume":"1","author":"LA Pikor","year":"2015","unstructured":"Pikor, L. A., Bell, J. C. & Diallo, J. S. Oncolytic viruses: exploiting cancer\u2019s deal with the devil. Trends Cancer 1, 266\u2013277 (2015).","journal-title":"Trends Cancer"},{"key":"53347_CR11","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1158\/0008-5472.CAN-11-2612","volume":"72","author":"IA Prior","year":"2012","unstructured":"Prior, I. A., Lewis, P. D. & Mattos, C. A comprehensive survey of ras mutations in cancer. Cancer Res. 72, 2457\u20132467 (2012).","journal-title":"Cancer Res."},{"key":"53347_CR12","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/sj.bjc.6606053","volume":"104","author":"M Kim","year":"2011","unstructured":"Kim, M. et al. Attenuated reovirus displays oncolysis with reduced host toxicity. Br. J. Cancer 104, 290\u2013299 (2011).","journal-title":"Br. J. Cancer"},{"key":"53347_CR13","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1517\/14712590903002039","volume":"9","author":"K Kelly","year":"2009","unstructured":"Kelly, K. et al. Reovirus-based therapy for cancer. Expert Opin. Biol. Ther. 9, 817\u2013830 (2009).","journal-title":"Expert Opin. Biol. Ther."},{"key":"53347_CR14","first-page":"187","volume":"45","author":"M Kim","year":"2007","unstructured":"Kim, M., Chung, Y. H. & Johnston, R. N. Reovirus and tumor oncolysis. J. Microbiol. 45, 187\u2013192 (2007).","journal-title":"J. Microbiol."},{"key":"53347_CR15","doi-asserted-by":"publisher","first-page":"667","DOI":"10.3390\/v12060667","volume":"12","author":"AT Abad","year":"2020","unstructured":"Abad, A. T. & Danthi, P. Recognition of reovirus RNAs by the Innate Immune System. Viruses 12, 667 (2020).","journal-title":"Viruses"},{"key":"53347_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-11469-6","volume":"7","author":"ML Stanifer","year":"2017","unstructured":"Stanifer, M. L., Kischnick, C., Rippert, A., Albrecht, D. & Boulant, S. Reovirus inhibits interferon production by sequestering IRF3 into viral factories. Sci. Rep. 7, 10873 (2017).","journal-title":"Sci. Rep."},{"key":"53347_CR17","first-page":"7242","volume":"7","author":"C Zhao","year":"2014","unstructured":"Zhao, C. et al. Dysregulation of JAM-A plays an important role in human tumor progression. Int. J. Clin. Exp. Patho. 7, 7242\u20137248 (2014).","journal-title":"Int. J. Clin. Exp. Patho."},{"key":"53347_CR18","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1038\/sj.mt.6300207","volume":"15","author":"T Alain","year":"2007","unstructured":"Alain, T. et al. Proteolytic disassembly is a critical determinant for reovirus oncolysis. Mol. Ther. 15, 1512\u20131521 (2007).","journal-title":"Mol. Ther."},{"key":"53347_CR19","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1038\/sj.mt.6300179","volume":"15","author":"P Marcato","year":"2007","unstructured":"Marcato, P., Shmulevitz, M., Pan, D., Stoltz, D. & Lee, P. W. Ras transformation mediates reovirus oncolysis by enhancing virus uncoating, particle infectivity, and apoptosis-dependent release. Mol. Ther. 15, 1522\u20131530 (2007).","journal-title":"Mol. Ther."},{"key":"53347_CR20","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.3390\/cells11111757","volume":"11","author":"C DeAntoneo","year":"2022","unstructured":"DeAntoneo, C., Danthi, P. & Balachandran, S. Reovirus activated cell death pathways. Cells 11, 1757 (2022).","journal-title":"Cells"},{"key":"53347_CR21","first-page":"1","volume":"289","author":"P Clarke","year":"2005","unstructured":"Clarke, P., Richardson-Burns, S. M., DeBiasi, R. L. & Tyler, K. L. Mechanisms of apoptosis during reovirus infection. Curr. Top. Microbiol. Immunol. 289, 1\u201324 (2005).","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"53347_CR22","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/nature13590","volume":"514","author":"D Goubau","year":"2014","unstructured":"Goubau, D. et al. Antiviral immunity via RIG-I-mediated recognition of RNA bearing 5\u2019-diphosphates. Nature 514, 372\u2013375 (2014).","journal-title":"Nature"},{"key":"53347_CR23","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1128\/JVI.01080-07","volume":"82","author":"YM Loo","year":"2008","unstructured":"Loo, Y. M. et al. Distinct RIG-I and MDA5 signaling by RNA viruses in innate immunity. J. Virol. 82, 335\u2013345 (2008).","journal-title":"J. Virol."},{"key":"53347_CR24","doi-asserted-by":"publisher","first-page":"8135","DOI":"10.1128\/JVI.74.17.8135-8139.2000","volume":"74","author":"P Clarke","year":"2000","unstructured":"Clarke, P. et al. Reovirus-induced apoptosis is mediated by TRAIL. J. Virol. 74, 8135\u20138139 (2000).","journal-title":"J. Virol."},{"key":"53347_CR25","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1038\/sj.cdd.4401045","volume":"9","author":"DJ Kominsky","year":"2002","unstructured":"Kominsky, D. J., Bickel, R. J. & Tyler, K. L. Reovirus-induced apoptosis requires both death receptor- and mitochondrial-mediated caspase-dependent pathways of cell death. Cell Death Differ. 9, 926\u2013933 (2002).","journal-title":"Cell Death Differ."},{"key":"53347_CR26","doi-asserted-by":"publisher","first-page":"e0168233","DOI":"10.1371\/journal.pone.0168233","volume":"12","author":"C Thirukkumaran","year":"2017","unstructured":"Thirukkumaran, C. et al. PUMA and NF-kB are cell signaling predictors of reovirus oncolysis of breast cancer. PLoS ONE 12, e0168233 (2017).","journal-title":"PLoS ONE"},{"key":"53347_CR27","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1128\/JVI.05924-11","volume":"86","author":"JJ Knowlton","year":"2012","unstructured":"Knowlton, J. J., Dermody, T. S. & Holm, G. H. Apoptosis induced by mammalian reovirus is beta interferon (IFN) independent and enhanced by IFN regulatory factor 3- and NF-kappaB-dependent expression of Noxa. J. Virol. 86, 1650\u20131660 (2012).","journal-title":"J. Virol."},{"key":"53347_CR28","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02404-16","volume":"91","author":"AK Berger","year":"2017","unstructured":"Berger, A. K. et al. Viral RNA at two stages of reovirus infection is required for the induction of necroptosis. J. Virol. 91, e02404-16 (2017).","journal-title":"J. Virol."},{"key":"53347_CR29","doi-asserted-by":"publisher","first-page":"413","DOI":"10.4161\/auto.22867","volume":"9","author":"CM Thirukkumaran","year":"2013","unstructured":"Thirukkumaran, C. M. et al. Reovirus modulates autophagy during oncolysis of multiple myeloma. Autophagy 9, 413\u2013414 (2013).","journal-title":"Autophagy"},{"key":"53347_CR30","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.3390\/cancers12113219","volume":"12","author":"L Muller","year":"2020","unstructured":"Muller, L., Berkeley, R., Barr, T., Ilett, E. & Errington-Mais, F. Past, present and future of oncolytic reovirus. Cancers 12, 3219 (2020).","journal-title":"Cancers"},{"key":"53347_CR31","doi-asserted-by":"publisher","first-page":"454","DOI":"10.5483\/BMBRep.2015.48.8.076","volume":"48","author":"M Kim","year":"2015","unstructured":"Kim, M. Naturally occurring reoviruses for human cancer therapy. BMB Rep. 48, 454\u2013460 (2015).","journal-title":"BMB Rep."},{"key":"53347_CR32","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1038\/sj.bjc.6603363","volume":"95","author":"T Alain","year":"2006","unstructured":"Alain, T. et al. The oncolytic effect in vivo of reovirus on tumour cells that have survived reovirus cell killing in vitro. Br. J. Cancer 95, 1020\u20131027 (2006).","journal-title":"Br. J. Cancer"},{"key":"53347_CR33","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1038\/sj.onc.1210189","volume":"26","author":"M Kim","year":"2007","unstructured":"Kim, M. et al. Acquired resistance to reoviral oncolysis in Ras-transformed fibrosarcoma cells. Oncogene 26, 4124\u20134134 (2007).","journal-title":"Oncogene"},{"key":"53347_CR34","unstructured":"Kim, M. et al. Composition for inhibiting angiogenesis, containing reovirus as active ingredient. Patent WO2014204275A1 https:\/\/patents.google.com\/patent\/WO2014204275A1\/en (2014)."},{"key":"53347_CR35","doi-asserted-by":"crossref","unstructured":"Voskoboynik, M. et al. A first-in-human phase 1 dose-escalation and expansion study of intratumoral oncolytic reovirus (RC402) as a monotherapy or in combination with pembrolizumab in advanced solid tumors. Cancer Res. 84, CT186 (2024).","DOI":"10.1158\/1538-7445.AM2024-CT186"},{"key":"53347_CR36","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/sj.mt.6300403","volume":"16","author":"P Forsyth","year":"2008","unstructured":"Forsyth, P. et al. A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas. Mol. Ther. 16, 627\u2013632 (2008).","journal-title":"Mol. Ther."},{"key":"53347_CR37","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1038\/gt.2008.21","volume":"15","author":"CL White","year":"2008","unstructured":"White, C. L. et al. Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial. Gene Ther. 15, 911\u2013920 (2008).","journal-title":"Gene Ther."},{"key":"53347_CR38","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1200\/JCO.19.02985","volume":"38","author":"GV Goldmacher","year":"2020","unstructured":"Goldmacher, G. V. et al. Response Criteria for Intratumoral Immunotherapy in Solid Tumors: itRECIST. J. Clin. Oncol. 38, 2667\u20132676 (2020).","journal-title":"J. Clin. Oncol."},{"key":"53347_CR39","doi-asserted-by":"publisher","first-page":"31","DOI":"10.4049\/jimmunol.1601145","volume":"198","author":"MA Aznar","year":"2017","unstructured":"Aznar, M. A. et al. Intratumoral delivery of immunotherapy-act locally, think globally. J. Immunol. 198, 31\u201339 (2017).","journal-title":"J. Immunol."},{"key":"53347_CR40","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.addr.2017.05.011","volume":"114","author":"L Milling","year":"2017","unstructured":"Milling, L., Zhang, Y. & Irvine, D. J. Delivering safer immunotherapies for cancer. Adv. Drug Deliv. Rev. 114, 79\u2013101 (2017).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"53347_CR41","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/s41434-020-00205-x","volume":"28","author":"KJ Kim","year":"2021","unstructured":"Kim, K. J. et al. Antitumor effects of IL-12 and GM-CSF co-expressed in an engineered oncolytic HSV-1. Gene Ther. 28, 186\u2013198 (2021).","journal-title":"Gene Ther."},{"key":"53347_CR42","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/nrc1886","volume":"6","author":"P Mehlen","year":"2006","unstructured":"Mehlen, P. & Puisieux, A. Metastasis: a question of life or death. Nat. Rev. Cancer 6, 449\u2013458 (2006).","journal-title":"Nat. Rev. Cancer"},{"key":"53347_CR43","doi-asserted-by":"publisher","first-page":"309","DOI":"10.4143\/crt.2019.161","volume":"52","author":"E Cho","year":"2020","unstructured":"Cho, E. et al. Characterization of oncolytic vaccinia virus harboring the human IFNB1 and CES2 transgenes. Cancer Res. Treat. 52, 309\u2013319 (2020).","journal-title":"Cancer Res. Treat."},{"key":"53347_CR44","doi-asserted-by":"publisher","first-page":"138ra","DOI":"10.1126\/scitranslmed.3003578","volume":"4","author":"RA Adair","year":"2012","unstructured":"Adair, R. A. et al. Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients. Sci. Transl. Med. 4, 138ra\u2013177 (2012).","journal-title":"Sci. Transl. Med."},{"key":"53347_CR45","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1158\/1078-0432.CCR-18-1932","volume":"25","author":"HJ Chon","year":"2019","unstructured":"Chon, H. J. et al. Tumor microenvironment remodeling by intratumoral oncolytic vaccinia virus enhances the efficacy of immune-checkpoint blockade. Clin. Cancer Res. 25, 1612\u20131623 (2019).","journal-title":"Clin. Cancer Res."},{"key":"53347_CR46","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.3389\/fimmu.2018.01299","volume":"9","author":"Y Guo","year":"2018","unstructured":"Guo, Y., Tian, X., Wang, X. & Xiao, Z. Adverse effects of immunoglobulin therapy. Front. Immunol. 9, 1299 (2018).","journal-title":"Front. Immunol."},{"key":"53347_CR47","doi-asserted-by":"publisher","first-page":"4","DOI":"10.4161\/gmic.19320","volume":"3","author":"HJ Wu","year":"2012","unstructured":"Wu, H. J. & Wu, E. The role of gut microbiota in immune homeostasis and autoimmunity. Gut Microbes 3, 4\u201314 (2012).","journal-title":"Gut Microbes"},{"key":"53347_CR48","doi-asserted-by":"publisher","first-page":"4430","DOI":"10.1172\/JCI86674","volume":"126","author":"S Fujisaka","year":"2016","unstructured":"Fujisaka, S. et al. Antibiotic effects on gut microbiota and metabolism are host dependent. J. Clin. Investig. 126, 4430\u20134443 (2016).","journal-title":"J. Clin. Investig."},{"key":"53347_CR49","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/s41385-021-00445-z","volume":"15","author":"CJ Tyler","year":"2022","unstructured":"Tyler, C. J. et al. Antibody secreting cells are critically dependent on integrin \u03b14\u03b27\/MAdCAM-1 for intestinal recruitment and control of the microbiota during chronic colitis. Mucosal Immunol 15, 109\u2013119 (2022).","journal-title":"Mucosal Immunol"},{"key":"53347_CR50","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.it.2012.10.004","volume":"34","author":"MB Fuertes","year":"2013","unstructured":"Fuertes, M. B., Woo, S. R., Burnett, B., Fu, Y. X. & Gajewski, T. F. Type I interferon response and innate immune sensing of cancer. Trends Immunol. 34, 67\u201373 (2013).","journal-title":"Trends Immunol."},{"key":"53347_CR51","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1038\/sj.cgt.7701068","volume":"14","author":"T Alain","year":"2007","unstructured":"Alain, T. et al. Reovirus decreases azoxymethane-induced aberrant crypt foci and colon cancer in a rodent model. Cancer Gene Ther. 14, 867\u2013872 (2007).","journal-title":"Cancer Gene Ther."},{"key":"53347_CR52","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.it.2023.06.007","volume":"44","author":"M Chelvanambi","year":"2023","unstructured":"Chelvanambi, M. & Wargo, J. A. MAdCAM-1: a newly identified microbial \u2018gut check\u2019 for T cells. Trends Immunol. 44, 568\u2013570 (2023).","journal-title":"Trends Immunol."},{"key":"53347_CR53","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/0-387-33778-4_10","volume":"579","author":"P Brandtzaeg","year":"2006","unstructured":"Brandtzaeg, P., Carlsen, H. S. & Halstensen, T. S. The B-cell system in inflammatory bowel disease. Adv. Exp. Med. Biol. 579, 149\u2013167 (2006).","journal-title":"Adv. Exp. Med. Biol."},{"key":"53347_CR54","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1126\/science.1132742","volume":"314","author":"JR Mora","year":"2006","unstructured":"Mora, J. R. et al. Generation of gut-homing IgA-secreting B cells by intestinal dendritic cells. Science 314, 1157\u20131160 (2006).","journal-title":"Science"},{"key":"53347_CR55","doi-asserted-by":"publisher","first-page":"eabo2296","DOI":"10.1126\/science.abo2296","volume":"380","author":"M Fidelle","year":"2023","unstructured":"Fidelle, M. et al. A microbiota-modulated checkpoint directs immunosuppressive intestinal T cells into cancers. Science 380, eabo2296 (2023).","journal-title":"Science"},{"key":"53347_CR56","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s40425-019-0574-4","volume":"7","author":"J Fessler","year":"2019","unstructured":"Fessler, J., Matson, V. & Gajewski, T. F. Exploring the emerging role of the microbiome in cancer immunotherapy. J. Immunother. Cancer 7, 108 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"53347_CR57","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/s41392-021-00687-0","volume":"6","author":"D Li","year":"2021","unstructured":"Li, D. & Wu, M. Pattern recognition receptors in health and diseases. Signal. Transduct. Target. Ther. 6, 291 (2021).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"53347_CR58","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1126\/science.aax0701","volume":"369","author":"A Fluckiger","year":"2020","unstructured":"Fluckiger, A. et al. Cross-reactivity between tumor MHC class I-restricted antigens and an enterococcal bacteriophage. Science 369, 936\u2013942 (2020).","journal-title":"Science"},{"key":"53347_CR59","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.it.2022.11.002","volume":"44","author":"C Villemin","year":"2023","unstructured":"Villemin, C. et al. The heightened importance of the microbiome in cancer immunotherapy. Trends Immunol. 44, 44\u201359 (2023).","journal-title":"Trends Immunol."},{"key":"53347_CR60","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1086\/428911","volume":"191","author":"JH Tai","year":"2005","unstructured":"Tai, J. H. et al. Prevalence of reovirus-specific antibodies in young children in Nashville, Tennessee. J. Infect. Dis. 191, 1221\u20131224 (2005).","journal-title":"J. Infect. Dis."},{"key":"53347_CR61","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1158\/2326-6066.CIR-18-0337","volume":"7","author":"RP Kataru","year":"2019","unstructured":"Kataru, R. P. et al. Tumor lymphatic function regulates tumor inflammatory and immunosuppressive microenvironments. Cancer Immunol. Res. 7, 1345\u20131358 (2019).","journal-title":"Cancer Immunol. Res."},{"key":"53347_CR62","doi-asserted-by":"publisher","first-page":"4703","DOI":"10.3390\/cancers15194703","volume":"15","author":"JK Woo","year":"2023","unstructured":"Woo, J. K. et al. Dual-Armed oncolytic myxoma virus encoding IFN-\u03b3 and CD47 promotes Lymphocyte infiltration and tumor suppression of syngeneic murine melanoma. Cancers 15, 4703 (2023).","journal-title":"Cancers"},{"key":"53347_CR63","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1292\/jvms.14-0570","volume":"77","author":"M Igase","year":"2015","unstructured":"Igase, M. et al. The oncolytic effects of reovirus in canine solid tumor cell lines. J. Vet. Med. Sci. 77, 541\u2013548 (2015).","journal-title":"J. Vet. Med. Sci."},{"key":"53347_CR64","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1002\/jat.1396","volume":"29","author":"HY Joo","year":"2009","unstructured":"Joo, H. Y., Lim, K. & Lim, K. T. Phytoglycoprotein (150 kDa) isolated from Solanum nigrum Linne has a preventive effect on dextran sodium sulfate-induced colitis in A\/J mouse. J. Appl. Toxicol. 29, 207\u2013213 (2009).","journal-title":"J. Appl. Toxicol."},{"key":"53347_CR65","doi-asserted-by":"publisher","first-page":"e004799","DOI":"10.1136\/jitc-2022-004799","volume":"10","author":"WS Lee","year":"2022","unstructured":"Lee, W. S. et al. Intratumoral immunotherapy using a TLR2\/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade. J. Immunother. Cancer 10, e004799 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"53347_CR66","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1038\/s41587-023-01688-w","volume":"41","author":"A Blanco-M\u00edguez","year":"2023","unstructured":"Blanco-M\u00edguez, A. et al. Extending and improving metagenomic taxonomic profiling with uncharacterized species using MetaPhlAn 4. Nat. Biotechnol. 41, 1633\u20131644 (2023).","journal-title":"Nat. Biotechnol."},{"key":"53347_CR67","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/nmeth.3176","volume":"12","author":"B Buchfink","year":"2015","unstructured":"Buchfink, B., Xie, C. & Huson, D. H. Fast and sensitive protein alignment using DIAMOND. Nat. Methods. 12, 59\u201360 (2015).","journal-title":"Nat. Methods."},{"key":"53347_CR68","doi-asserted-by":"crossref","unstructured":"Go E. J., et al. Systemic delivery of a STING agonist-loaded positively charged liposome selectively targets tumor immune microenvironment and suppresses tumor angiogenesis. Small 19, e2300544 (2023).","DOI":"10.1002\/smll.202300544"},{"key":"53347_CR69","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2021.2005280","volume":"10","author":"JH Kim","year":"2021","unstructured":"Kim, J. H. et al. Deep learning model enables the discovery of a novel immunotherapeutic agent regulating the kynurenine pathway. Oncoimmunology 10, 2005280 (2021).","journal-title":"Oncoimmunology"},{"key":"53347_CR70","doi-asserted-by":"publisher","first-page":"4350","DOI":"10.1172\/JCI125413","volume":"129","author":"H Yang","year":"2019","unstructured":"Yang, H. et al. STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade. J. Clin. Investig. 129, 4350\u20134364 (2019).","journal-title":"J. Clin. Investig."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-53347-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-53347-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-53347-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T11:03:17Z","timestamp":1729854197000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-53347-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,22]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["53347"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-53347-6","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,22]]},"assertion":[{"value":"19 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.K. has a consulting or advisory role at Roche, MSD, BMS, ONO, Oncocross, Virocure, and Sillajen, and has received research grants from Panolos Bioscience, Boryung Pharmaceuticals, Oncocross, Sillajen, and Virocure. H.J.C. has a consulting or advisory role at Roche, Bayer, ONO, MSD, BMS, Celgene, Sanofi, Servier, AstraZeneca, Eisai, Sillajen, Menarini, GreenCross Cell, and Virocure and has received research grants from Panolos Bioscience, Roche and Boryung Pharmaceuticals. E.G., K-H.S. and D.G.P. are employees of Virocure. T.A. has a consulting and advisory role at Virocure, CuroV Science and Genvira Biosciences. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9092"}}